Sichuan Hebang Biotechnology Co Ltd (603077) fair value: what the stock is really worth
We calculate from audited financials what Sichuan Hebang Biotechnology Co Ltd is really worth. The fair value tells you whether the price is too high or too low, the quality score (0 to 100) how solid the business behind it is. 26 models, 37 quality factors, updated daily.
Watch Sichuan Hebang Biotechnology Co Ltd for free, get notified when fair value or trend changes. Plus fair value for all 35,000+ stocks, 14 days of Pro free, no card.Watch for free
69 individual criteria per stock, every one traceableSee the method →
Price vs Fair Value
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Sep 13, 2026.
How to read this chart
60‑month range ¥1.51 – ¥4.69 · fair‑value band ¥0.3004 – ¥0.8412 · the ¥2.37 price screens above the ¥0.6209 fair value. Green steps = our fair value per fiscal year (point-in-time, no hindsight). Dashed = 300-day average. As of Sep 13, 2026.
Sichuan Hebang Biotechnology Corporation Limited provides agricultural, chemical, and new material products. It offers biological pesticides, biological veterinary drugs, and methionine products; and sodium carbonate, ammonium chloride, soda ash, diglyphosate, glyphosate, and brine.
Show more
Sichuan Hebang Biotechnology Corporation Limited provides agricultural, chemical, and new material products. It offers biological pesticides, biological veterinary drugs, and methionine products; and sodium carbonate, ammonium chloride, soda ash, diglyphosate, glyphosate, and brine. The company provides original glass and smart glass, special glass, low-e coated glass, and photovoltaic packaging materials and products, as well as photovoltaic glass and module products. In addition, it engages in the supply of oil and gas. The company was formerly known as SichuanHebang Biotechnology Co.,Ltd. and changed its name to Sichuan Hebang Biotechnology Corporation Limited in April 2021. The company was founded in 2002 and is based in Leshan, China.
Stock analysis
Sichuan Hebang Biotechnology Co Ltd (603077) currently trades at ¥2.37, while our model-based Fair Value estimate is ¥0.6209, implying the stock looks roughly 281.7% overvalued today.
Show more
Valuation
Bull case: the Asset-Based group reads highest at a median of ¥1.36 per share, and 0 of the 8 models we run sit above the ¥2.37 price.
Bear case: the Dividend Discount group reads lowest at ¥0.2300, and 8 of the 8 models stay below the price. Evidence for this calculation is low.
Scenario range: ¥0.3004 (bear) to ¥0.8412 (bull), the price of ¥2.37 sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.
Quality & growth
The Quality Score stands at 39/100 (below-average quality), in the Basic Materials sector.
Weak Growth: Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
Sichuan Hebang Biotechnology Co Ltd reported revenue of 7.2B CNY in FY2025 versus 10.0B CNY in FY2021, a compound −7.9%/yr. Reported net income was −536M CNY in FY2025.
Key figures
Market cap 20.9B CNY (≈ $3.1B) · P/S ratio 3.15 · EPS (TTM) ¥−0.0500 · Dividend yield 0.6% · Net margin −7.5% · Return on equity −3.0% · Return on assets (EBIT) 9.1% · Operating margin 14.0%.
Competitive moat
Our AI-assisted moat analysis scores the competitive advantage at 37 out of 100 (low confidence).
What moves the price
The share trades about 33% below its 52-week high and 39% above its 52-week low, currently below its 200-day average.
For context, the median of 10 Basic Materials peers we cover trades at −44% fair-value upside, at −74%, 603077 screens richer than that median.
Fair Value models
Bear ¥0.3004Fair Value ¥0.6209Bull ¥0.8412
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model.Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target.Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card.20/100
Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
Revenue growth 1 year
−15.9%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−18.0%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+6.4%
Revenue growth 16 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+14.3%
’14
’15
’16
’17
’18
’19
’20
’21
’22
’23
’24
’25
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
8.4% (2020) → 3.7% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
Compare Sichuan Hebang Biotechnology Co Ltd with another stock
Price, fair value, quality and upside side by side.
Free, no sign-up
Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Chemicals · 350 stocks
Beats the industry median on 4/11 measures
Overall it trails its industry peers.
Valuation
Quality Score39 · Bottom 25%
Fair Value upside−90% · Bottom 25%
Profitability
Return on assets0% · Below median
Net margin (TTM)−5% · Bottom 25%
Operating margin (TTM)14% · Top 25%
Growth and dividend
Revenue growth−20% · Bottom 25%
Dividend yield (TTM)0.6% · Bottom 25%
Balance sheet
Debt / equity0.34× · Above median
Valuation Multiplesvs Chemicals median · lower = cheaper
P/B0.18× · Cheapest 25%
P/S (TTM)0.46× · Cheaper than median
EV/EBITDA2.6× · Cheapest 25%
Strength profile in five axes (Snowflake)
This stockSector peers
VALUE (fair-value potential)0· sector 1
FUTURE (revenue growth)0· sector 22
PAST (return on equity)0· sector 19
HEALTH (low debt)83· sector 94
DIVIDEND (yield)13· sector 31
VALUE 0: the price sits above our fair-value range.
For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.
Cite: Fair Value Calculator (2026). "Sichuan Hebang Biotechnology Co Ltd Fair Value". https://www.fairvalue-calculator.com/stock/603077
Frequently asked questions
Is Sichuan Hebang Biotechnology Co Ltd (603077) overvalued or undervalued?
As of Sep 13, 2026, our model estimates a fair value of ¥0.6209 versus a price of ¥2.37, about −74% upside (overvalued).
What is the fair value of 603077?
Our model-based fair value for Sichuan Hebang Biotechnology Co Ltd is ¥0.6209 (as of Sep 13, 2026), built from audited fundamentals. The current price: ¥2.37.
What is the quality score of 603077?
Sichuan Hebang Biotechnology Co Ltd has a Quality Score of 39/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Sichuan Hebang Biotechnology Co Ltd (603077)?
Our model-based price target is the fair value of ¥0.6209 (as of Sep 13, 2026) from 8 valuation models. Cautious scenario ¥0.3004, optimistic scenario ¥0.8412. It is a calculation from audited fundamentals, not an analyst target.
What is the Sichuan Hebang Biotechnology Co Ltd stock forecast for 2026?
Our models put fair value at ¥0.6209, about −74% upside versus a price of ¥2.37 (overvalued). Cautious scenario ¥0.3004, optimistic scenario ¥0.8412. The calculation is refreshed regularly with new filings.
What is the revenue of Sichuan Hebang Biotechnology Co Ltd (603077)?
Sichuan Hebang Biotechnology Co Ltd reported trailing-twelve-month revenue of about 6.8B CNY (latest available figure, as of Sep 13, 2026).
Does Sichuan Hebang Biotechnology Co Ltd pay a dividend?
Sichuan Hebang Biotechnology Co Ltd currently shows a dividend yield of about 0.63% relative to its recent price (as of Sep 13, 2026).
What is the intrinsic value of Sichuan Hebang Biotechnology Co Ltd (603077)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Sichuan Hebang Biotechnology Co Ltd it is ¥0.6209 per share (as of Sep 13, 2026), against a price of ¥2.37. It is the blended result of 8 valuation models (cash flow, earnings, asset, dividend).
Is Sichuan Hebang Biotechnology Co Ltd stock overvalued or undervalued in 2026?
As of Sep 13, 2026, 603077 trades above its calculated fair value: price ¥2.37, fair value ¥0.6209, a gap of about −74% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of 603077?
No. The price is what the market pays today (¥2.37); the fair value is what the company's own numbers justify (¥0.6209). For Sichuan Hebang Biotechnology Co Ltd the two are ¥1.75 per share apart. That gap is exactly why we show both numbers side by side.
How much is Sichuan Hebang Biotechnology Co Ltd worth?
The market values Sichuan Hebang Biotechnology Co Ltd at about 20.9B CNY (market capitalisation, as of Sep 13, 2026). Per share that is ¥2.37; our models calculate a fair value of ¥0.6209 per share.
What do the bullish and bearish scenarios say about 603077?
Our models span a range for Sichuan Hebang Biotechnology Co Ltd: cautious scenario ¥0.3004, base ¥0.6209, optimistic ¥0.8412 per share (as of Sep 13, 2026, price ¥2.37). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Sichuan Hebang Biotechnology Co Ltd (603077)?
Balance-sheet figures for Sichuan Hebang Biotechnology Co Ltd (as of Sep 13, 2026): return on equity −3.0%, debt of 0.34 per unit of equity. They feed the Quality Score of 39/100, which measures business quality independently of the share price.
How far is 603077 from its 52-week high?
Sichuan Hebang Biotechnology Co Ltd trades at ¥2.37, about 33% below its 52-week high of ¥3.54 and 39% above the low of ¥1.71 (as of Sep 13, 2026). Distance from the high says nothing about value: that is what the fair value of ¥0.6209 is for.
Which stocks are comparable to Sichuan Hebang Biotechnology Co Ltd?
From the same area (Basic Materials) we also value BASF SE, Saudi Basic Industries Corporation, A. Schulman, Inc, Ningxia Baofeng Energy Group, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Sichuan Hebang Biotechnology Co Ltd stock attractive at the current price?
The data as of Sep 13, 2026: price ¥2.37, calculated fair value ¥0.6209 (−74%), Quality Score 39/100, from 8 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of 603077 calculated?
We run Sichuan Hebang Biotechnology Co Ltd through 8 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of ¥0.6209, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 15.8 % above its aggregate fair value. Sichuan Hebang Biotechnology Co Ltd itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What should I pay attention to with Sichuan Hebang Biotechnology Co Ltd right now?
The price sits above even our optimistic bull case (¥0.8412). The favourable scenario is already priced in. Weak quality (39/100) and above fair value at the same time, the margin of safety is missing on both counts. The model range is unusually wide (¥0.3004 to ¥0.8412). The outcome hinges heavily on assumptions, so read the point estimate with caution. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.
Where does the earnings growth of Sichuan Hebang Biotechnology Co Ltd (603077) come from?
Earnings per share at Sichuan Hebang Biotechnology Co Ltd grew +23.5 % a year from 2013 to 2024. Broken into its drivers: revenue per share +17.0 %, EBIT margin +7.8 %, tax rate −1.3 %, residual (interest, one-offs) −0.8 %. The four rates multiply to the earnings growth rate, they do not add up. Start and end are three-year averages so a single exceptional year does not distort the result.
Key figures of Sichuan Hebang Biotechnology Co Ltd
How large is the market capitalisation of Sichuan Hebang Biotechnology Co Ltd (603077)?
The market capitalisation of Sichuan Hebang Biotechnology Co Ltd is 20.9B CNY (≈ $3.1B). The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of Sichuan Hebang Biotechnology Co Ltd (603077)?
The price-to-sales ratio of Sichuan Hebang Biotechnology Co Ltd is 3.15 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of Sichuan Hebang Biotechnology Co Ltd (603077)?
Earnings per share at Sichuan Hebang Biotechnology Co Ltd are ¥−0.0500. Earnings per share over the last twelve months: total profit spread across every single share.
What is the dividend yield of Sichuan Hebang Biotechnology Co Ltd (603077)?
The dividend yield of Sichuan Hebang Biotechnology Co Ltd is 0.6%. Yearly dividend relative to the share price. 3% pays 3 per 100 invested. Below: how much of profit is used for it.
What is the net margin of Sichuan Hebang Biotechnology Co Ltd (603077)?
The net margin of Sichuan Hebang Biotechnology Co Ltd is −7.5% (fiscal year 2025). How much of every unit of revenue ends up as profit. 10% means 10 cents of profit per dollar of sales.
What is the return on equity of Sichuan Hebang Biotechnology Co Ltd (603077)?
The return on equity (ROE) of Sichuan Hebang Biotechnology Co Ltd is −3.0% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Sichuan Hebang Biotechnology Co Ltd (603077)?
On an EBIT basis the return on assets of Sichuan Hebang Biotechnology Co Ltd is 9.1% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Sichuan Hebang Biotechnology Co Ltd (603077)?
The operating margin of Sichuan Hebang Biotechnology Co Ltd is 14.0% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Sichuan Hebang Biotechnology Co Ltd (603077)?
Revenue at Sichuan Hebang Biotechnology Co Ltd is growing −19.6% versus a year earlier (3y avg −18.0%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How fast are earnings growing at Sichuan Hebang Biotechnology Co Ltd (603077)?
Earnings per share at Sichuan Hebang Biotechnology Co Ltd are growing +13.1% versus a year earlier. How much earnings per share grew versus a year earlier.
How much free cash flow does Sichuan Hebang Biotechnology Co Ltd (603077) generate?
The free cash flow of Sichuan Hebang Biotechnology Co Ltd is −183M CNY (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does Sichuan Hebang Biotechnology Co Ltd (603077) carry?
The net debt of Sichuan Hebang Biotechnology Co Ltd is 1.7B CNY (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed
Watch Sichuan Hebang Biotechnology Co Ltd in the live analysis
One click puts Sichuan Hebang Biotechnology Co Ltd on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener. You can also try 14 days of Pro there, no card.
